Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Moderna

Netflix

Peloton

Zoom Video

The coronavirus pandemic has hit markets bad. But investors shouldn't shun stocks in April but should instead look for avenues to invest in areas under focus owing to rise in infected cases.

Top Stock Trades to Beat Coronavirus Blues in April

CRISPR Therapeutics

Gilead Sciences

Johnson & Johnson

Telesis Bio Inc

Vir Biotechnology

These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure.

7 Biotech Stocks to Buy That Could Beat the Coronavirus

Clorox

Citrix Systems

NVIDIA

SBA Communications

The disappointing performance in Q1 is not due to any economic, financial or geopolitical factors but instead a health hazard ??? the coronavirus pandemic.

6 Top S&P 500 Stocks That Have Surged Despite Worst-Ever Q1

Vertex Pharmaceuticals

One of these biotech stocks holds a monopoly in the market for drugs that treat cystic fibrosis; the other is looking to develop a treatment for COVID-19. Which one is the better buy today?

Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals

Looking for hot stocks for 2020? These five stocks in particular have steadily outperformed the broader market during the coronavirus crisis.

5 Hot Stocks for 2020 That Are Soaring While the Market Plunges

Algonquin Power & Utilities

American States Water

Grocery Outlet

Inmode Ltd

US Foods Holding

The current economic slowdown led by rise in coronavirus cases calls for investing in defensive stocks.

6 Defensive Stocks Worth Buying as Coronavirus Cases Rise

PLDT

Sprouts Farmers Markets

A handful of stocks have withstood the market mayhem in March, some of them are momentum players.

5 Top Momentum Stocks for April Amid Coronavirus-Led Turmoil

Abbott Labs

Tuesday's big stock charts feature three companies that are contributing, in their own ways, to the fight against the coronavirus.
The post 3 Big Stock Charts for Tuesday: Abbott Laboratories, Johnson & Johnson, and Regeneron Pharmaceuticals appeared first on InvestorPlace.

3 Big Stock Charts for Tuesday: Abbott Laboratories, Johnson & Johnson, and Regeneron Pharmaceuticals

These S&P 500 index components have held higher ground despite the pandemic and are poised to hit new highs.

The 3 Strongest Stocks in the S&P 500

Novartis

Sanofi

Teva Pharmaceutical

Measures currently being taken against COVID-19 are the only means of containing and suppressing the virus.

Big Pharma Advances on COVID-19

Regeneron Pharmaceuticals Inc. REGN, -0.61% and Sanofi SA SNY, -1.19% said Monday that the first patient in a global clinical trial testing Kevzara as a therapy for patients hospitalized with severe cases of COVID-19 has been treated.

First patient treated in Regeneron, Sanofi trial for COVID-19 treatment

ABIOMED

Arista Networks

Alphabet

Incyte

IPG Photonics

Intuitive Surgical

Skyworks Solutions

Given the near-term economic uncertainty surrounding the COVID-19 outbreak, investors have been shifting their focus from growth stocks to stocks that have the balance sheets and liquidity to weather the current downturn.

10 Stocks To Buy With Low Debt And High Liquidity

Inovio Pharmaceuticals

Mylan

An old malaria drug may unseat newer investigational coronavirus treatments -- if data is confirmed.

3 Things to Know if Chloroquine Wins the COVID-19 Treatment Race

Biogen

Roche Holding AG

Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.

Biotech Stocks Accelerate Efforts for Coronavirus Treatments

It is only a matter of time before this virus anxiety is a thing of the past.

Top 5 Drug Stocks To Stop The Coronavirus Pandemic

AbbVie

Vaxart

Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.

Coronavirus Drug Development Race to Boost These 4 Stocks

DexCom

eBay

Microsoft

The U.S. government and Senate reached an agreement to inject $2 trillion of stimulus to boost the U.S. economy amid the coronavirus-induced turmoil.

US Government Reaches Deal on Stimulus Package: 5 Top Picks

Both companies are fighting the coronavirus pandemic on multiple fronts. Here's which stock is the better pick for long-term investors.

Better Coronavirus Stock: Regeneron or Roche?

Amgen

Biotech companies have outperformed the general market -- and there are plenty of reasons to remain optimistic.

4 Reasons Biotech Stocks Are a Buy Right Now

Calix

CBIZ

Ensign Group

Turning Point Brands

Low-volatility stocks tend to hold up better in tough times. More interestingly, these stocks have done better over longer periods of time, even before the coronavirus-induced market crash.

Market is Wavering! Buy 5 Best Low-Volatility Stocks Now

Hint: It's not because of the biotech's blockbuster eye-disease drug.

Why Is Everyone Talking About Regeneron?

Bayer AG

FUJIFILM Holdings Corp

These drugs could be key to staving off COVID-19 until a vaccine is developed.

All the Drugs Proving Anecdotally Effective Against COVID-19, and the Companies That Make Them

Potential coronavirus treatments from Regeneron, Sanofi, and Gilead Sciences will get more chances to prove themselves effective.

Nonprofit Group Starts Multiple COVID-19 Clinical Studies

News for Regeneron Pharmaceuticals Stock (REGN)